Cite
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer
MLA
Arend, Rebecca C., et al. “Utilizing an Interim Futility Analysis of the OVAL Study (VB-111-701/GOG 3018) for Potential Reduction of Risk: A Phase III, Double Blind, Randomized Controlled Trial of Ofranergene Obadenovec (VB-111) and Weekly Paclitaxel in Patients with Platinum Resistant Ovarian Cancer.” Gynecologic Oncology, vol. 161, no. 2, May 2021, pp. 496–501. EBSCOhost, https://doi.org/10.1016/j.ygyno.2021.02.014.
APA
Arend, R. C., Monk, B. J., Herzog, T. J., Moore, K. N., Shapira-Frommer, R., Ledermann, J. A., Tewari, K. S., Secord, A. A., Rachmilewitz Minei, T., Freedman, L. S., Miller, A., Shmueli, S. F., Lavi, M., & Penson, R. T. (2021). Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecologic Oncology, 161(2), 496–501. https://doi.org/10.1016/j.ygyno.2021.02.014
Chicago
Arend, Rebecca C., Bradley J. Monk, Thomas J. Herzog, Kathleen N. Moore, Ronnie Shapira-Frommer, Jonathan A. Ledermann, Krishnansu S. Tewari, et al. 2021. “Utilizing an Interim Futility Analysis of the OVAL Study (VB-111-701/GOG 3018) for Potential Reduction of Risk: A Phase III, Double Blind, Randomized Controlled Trial of Ofranergene Obadenovec (VB-111) and Weekly Paclitaxel in Patients with Platinum Resistant Ovarian Cancer.” Gynecologic Oncology 161 (2): 496–501. doi:10.1016/j.ygyno.2021.02.014.